Literature DB >> 7513538

A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer.

V Srinivasan1, C H Brown, A G Turner.   

Abstract

Pain and haematuria are two of the most distressing symptoms in patients with advanced bladder cancer. The aim of palliative radiotherapy is to relieve these symptoms with the minimum of stress to the patient and with minimal side effects. Two treatment regimens were studied: hypofractionated radiotherapy giving 1700 cGy in two fractions over 3 days and conventional palliative radiotherapy giving 4500 cGy in 12 fractions over 26 days. This study assesses 41 patients, all with Grade II-III T3-4 transitional cell carcinomas of the bladder treated between 1982 and 1989, presenting with haematuria and local pain. Two-fraction (hypofractionated) treatment was given to 22 patients and conventional palliative radiotherapy to 19; patients were selected by performance status. The effect on haematuria was assessed as cleared, intermittent or persistent. Pain was assessed by noting reduction in the need for opiate analgesia. Any side effect was recorded. In the patients receiving two-fraction radiotherapy, 59% had clearance of the haematuria and in 73% there was improvement of their pain, compared with 16% and 37% respectively in those receiving conventional palliation. Survival of the two groups was 9.77 months and 14.47 months respectively. Side effects were trivial in both regimens. Radiotherapy given in two fractions for patients in poor general health is well tolerated and less distressing than the standard palliative regimen with 12 fractions. Haematuria and pain were more effectively palliated than with conventional treatment, though survival was shorter. We conclude that hypofractionated radiotherapy may be the palliative treatment of choice and the study supports the need for a prospective assessment of this treatment approach.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513538     DOI: 10.1016/s0936-6555(05)80362-0

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  7 in total

1.  Haemostatic radiation therapy for a bleeding intraductal papillary neoplasm of the biliary tree.

Authors:  Senthil Sundaravadanan; Manu Mathew; Thomas Samuel Ram; Philip Joseph
Journal:  BMJ Case Rep       Date:  2018-12-14

2.  Palliative radiation therapy for primary gastric melanoma.

Authors:  Jason M Slater; Ted C Ling; Jerry D Slater; Gary Y Yang
Journal:  J Gastrointest Oncol       Date:  2014-02

3.  Efficacy of Palliative Bladder Radiotherapy for Hematuria in Advanced Bladder Cancer Using Contemporary Radiotherapy Techniques.

Authors:  Jeremy Tey; Yu Yang Soon; Timothy Cheo; Kiat Huat Ooi; Francis Ho; Balamurugan Vellayappan; David Chia; Bee Choo Tai
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

4.  Hypofractionated radiotherapy as local hemostatic agent in advanced cancer.

Authors:  Malik Tariq Rasool; Najmi Arshad Manzoor; Syed Arshad Mustafa; Lone Mohammad Maqbool; Fir Afroz
Journal:  Indian J Palliat Care       Date:  2011-09

5.  Patterns of practice in palliative radiotherapy for bleeding tumours in the Netherlands; a survey study among radiation oncologists.

Authors:  Jennifer Strijbos; Yvette M van der Linden; Hanneke Vos-Westerman; Angela van Baardwijk
Journal:  Clin Transl Radiat Oncol       Date:  2019-01-11

6.  Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy.

Authors:  Nikola Cihoric; Susanne Crowe; Steffen Eychmüller; Daniel M Aebersold; Pirus Ghadjar
Journal:  Radiat Oncol       Date:  2012-08-03       Impact factor: 3.481

7.  Bleeding in Locally Invasive Pelvic Malignancies: Is Hypofractionated Radiation Therapy a Safe and Effective Non-Invasive Option for Securing Hemostasis? A Single Institution Perspective.

Authors:  Muhammad Shuja; Saadiya Nazli; Muhammad Atif Mansha; Asif Iqbal; Reham Mohamed; Mutahir A Tunio; Eyad F Alsaeed; Mushabbab Asiri; Yasser Bayoumi
Journal:  Cureus       Date:  2018-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.